Camrelizumab is a program-death receptor 1 (PD-1) inhibitor and has been approved by Chinese Food and Drug Administration in HCC.20 Meanwhile, apatinib, a highly selective tyrosinase inhibitor acting on vascular endothelial growth factor 2, which is first developed in China, has shown a certain efficacy in patients with advanced HCC.21 22 Recently, the combination therapy of camrelizumab plus apatinib as first-line and second-line therapy in patients with HCC has shown a certain efficacy profile. Here, TYR is linked to hepatocellular carcinoma.